446 related articles for article (PubMed ID: 18762907)
21. Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease.
Targher G; Pichiri I; Zoppini G; Trombetta M; Bonora E
J Endocrinol Invest; 2012 May; 35(5):535-40. PubMed ID: 21795844
[TBL] [Abstract][Full Text] [Related]
22. Association among C-reactive protein, Fatty liver disease, and cardiovascular risk.
Lizardi-Cervera J; Chavez-Tapia NC; Pérez-Bautista O; Ramos MH; Uribe M
Dig Dis Sci; 2007 Sep; 52(9):2375-9. PubMed ID: 17458697
[TBL] [Abstract][Full Text] [Related]
23. The role of non-alcoholic fatty liver disease in cardiovascular disease.
Perseghin G
Dig Dis; 2010; 28(1):210-3. PubMed ID: 20460913
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic fatty liver disease and its association with cardiovascular disease.
Lizardi-Cervera J; Aguilar-Zapata D
Ann Hepatol; 2009; 8 Suppl 1():S40-3. PubMed ID: 19381123
[TBL] [Abstract][Full Text] [Related]
25. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?
Targher G; Chonchol M; Zoppini G; Abaterusso C; Bonora E
J Hepatol; 2011 May; 54(5):1020-9. PubMed ID: 21145850
[TBL] [Abstract][Full Text] [Related]
26. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
Muzurović E; Mikhailidis DP; Mantzoros C
Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
[TBL] [Abstract][Full Text] [Related]
27. Non-alcoholic fatty liver disease and cardiovascular risk.
Brea A; Puzo J
Int J Cardiol; 2013 Aug; 167(4):1109-17. PubMed ID: 23141876
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD.
Lonardo A; Sookoian S; Chonchol M; Loria P; Targher G
Curr Pharm Des; 2013; 19(29):5177-92. PubMed ID: 23432668
[TBL] [Abstract][Full Text] [Related]
29. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
Luo J; Xu L; Li J; Zhao S
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
[TBL] [Abstract][Full Text] [Related]
30. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?
Oni ET; Agatston AS; Blaha MJ; Fialkow J; Cury R; Sposito A; Erbel R; Blankstein R; Feldman T; Al-Mallah MH; Santos RD; Budoff MJ; Nasir K
Atherosclerosis; 2013 Oct; 230(2):258-67. PubMed ID: 24075754
[TBL] [Abstract][Full Text] [Related]
31. Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012).
George ES; Georgousopoulou EN; Mellor DD; Chrysohoou C; Pitsavos C; Panagiotakos DB
Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745097
[TBL] [Abstract][Full Text] [Related]
32. [Pediatric non-alcoholic fatty liver disease: recent advances and challenges].
Poggiogalle E; Olivero G; Anania C; Ferraro F; Pacifico L
Minerva Pediatr; 2010 Dec; 62(6):569-84. PubMed ID: 21042270
[TBL] [Abstract][Full Text] [Related]
33. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
Vernon G; Baranova A; Younossi ZM
Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
[TBL] [Abstract][Full Text] [Related]
34. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.
Scorletti E; Calder PC; Byrne CD
Endocrine; 2011 Dec; 40(3):332-43. PubMed ID: 21894514
[TBL] [Abstract][Full Text] [Related]
35. Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease.
Potze W; Siddiqui MS; Sanyal AJ
Semin Thromb Hemost; 2015 Jul; 41(5):488-93. PubMed ID: 26049073
[TBL] [Abstract][Full Text] [Related]
36. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences.
Del Ben M; Baratta F; Polimeni L; Angelico F
Intern Emerg Med; 2012 Oct; 7 Suppl 3():S291-6. PubMed ID: 23073870
[TBL] [Abstract][Full Text] [Related]
37. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
[TBL] [Abstract][Full Text] [Related]
38. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk?
Montecucco F; Mach F
Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):301-7. PubMed ID: 19075784
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
40. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics.
Riquelme A; Arrese M; Soza A; Morales A; Baudrand R; Pérez-Ayuso RM; González R; Alvarez M; Hernández V; García-Zattera MJ; Otarola F; Medina B; Rigotti A; Miquel JF; Marshall G; Nervi F
Liver Int; 2009 Jan; 29(1):82-8. PubMed ID: 18647235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
